Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix

Triple-Layer SIS Technology for Wound Management

FORT WORTH, Texas, May 11, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the introduction of OASIS® Ultra Tri-Layer Matrix, a natural extracellular matrix (ECM) material derived from three layers of porcine small intestinal submucosa (SIS). The three-layer construct of ECM was designed to incorporate increased structure into difficult-to-heal and chronic wounds.

"We are pleased to introduce OASIS® Ultra as an extension of our SIS product offerings," said Travis Baugh, President and Chief Operating Officer of Healthpoint Biotherapeutics. "The three-layer design provides healthcare professionals with an important therapeutic option for temporary ECM replacement in complex wounds where increased strength and thickness is called for as part of the treatment protocol."

SIS, the base technology for OASIS® Ultra, is among the most widely studied and published biomaterials, featured in more than 832 scientific publications.

OASIS® Ultra is indicated for the management of wounds including surgical, partial- and full-thickness, traumatic (including second degree burns), venous ulcers, chronic vascular ulcers, diabetic and pressure ulcers, and draining wounds.  The product should not be used in patients with known sensitivity to porcine material and is not indicated for use in third-degree burns.

About Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for tissue repair and healing. The company's diversified research and development strategy is presently centered around therapeutic enzymes, biologics and next-generation cell- and cell-matrix based therapies for the prevention and treatment of acute, chronic and burn-related wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix and OASIS® Ultra Tri-Layer Matrix. Healthpoint Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry-leading continuing education from The Wound Institute®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com.  Healthpoint Biotherapeutics is a DFB Pharmaceuticals, Inc., affiliate company, and is based in Fort Worth, Texas. For more information, visit the company website at www.Healthpoint.com.

HEALTHPOINT, SANTYL, THE WOUND INSTITUTE and THEWOUNDINSTITUTE.COM are registered trademarks of Healthpoint, Ltd.

OASIS is a registered trademark of Cook Biotech, Inc.

SOURCE Healthpoint Biotherapeutics

Suggested Articles

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.

Versantis will use the €16 million to trial a drug designed to remove toxic metabolites from liver disease patients.